论文部分内容阅读
阿霉素(ADM)是一种蒽环类抗肿瘤药,在多种肿瘤治疗中能取得显著的疗效。但由于该药可引起心脏毒性而限制了其临床使用。现就我科收治的15例以ADM为主联合化疗患者在使用阿霉素后即作心功能测定分析,报告如下。 本组病例均为我院收治的经病理学证实、不宜手术或放疗的晚期恶性肿瘤患者。无明显心脏,肝、肾功能障碍。除一例鼻咽癌于用药前二个月接受放疗外,余均未接受过放疗。15例中男10例,女5例,年龄29—68岁,平均49.8岁,肿瘤类型及化疗方案见表1。所有病人都以ADM为主的联合化疗。各种抗癌药物用法如下:ADM45mg/m~2iv第1天,CTX750mg/m~2 iv第1天,VCR 1.4 mg/m~2iv第1天,
Adriamycin (ADM) is an anthracycline antitumor drug that can achieve significant efficacy in a variety of cancer treatments. However, this drug limits its clinical use because it can cause cardiotoxicity. Now 15 patients undergoing treatment with ADM in our department were treated with doxorubicin for heart function analysis. The report is as follows. This group of patients were admitted to our hospital with pathologically confirmed, inoperable or radiotherapy patients with advanced malignant tumors. No obvious heart, liver and kidney dysfunction. Except one case of nasopharyngeal carcinoma receiving radiotherapy two months before the use of the drug, Yu had not received radiotherapy. In 15 cases, there were 10 males and 5 females, aged 29-68 years, with an average of 49.8 years. The tumor types and chemotherapy regimens are shown in Table 1. All patients had ADM-based combination chemotherapy. Various anticancer drugs were used as follows: ADM 45 mg/m~2iv on the first day, CTX 750 mg/m~2 iv on the first day, and VCR 1.4 mg/m~2iv on the first day.